The World Health Organization has issued its first guideline advising that GLP-1 medications be offered within comprehensive obesity treatment programs alongside healthy diets, regular physical activity, and counseling. Published in JAMA, the guidance frames obesity as a chronic, relapsing disease affecting more than one billion people worldwide and contributing substantially to illness, premature death, and economic burden.
WHO officials said GLP-1 therapies produce clinically meaningful weight loss and deliver broad metabolic benefits, but they cautioned that drugs alone will not solve the global obesity crisis. The recommendation is described as conditional: available evidence suggests benefits outweigh harms, yet long-term safety and effectiveness data are limited and drug prices must fall for access to broaden equitably.
Expert response
Clinicians and public health experts generally welcomed the guidance while noting important caveats. Several experts said the move recognizes obesity as a chronic disease and could spur manufacturers and policymakers to improve availability and affordability. Dietitians and surgeons emphasized that embracing medication does not replace lifestyle change; rather, combining medication with nutrition, activity, and behavioral support may be more sustainable for many patients.
Some commentators called GLP-1s a game changer because they are the first class of drugs to produce powerful, consistent weight loss and meaningful improvements in obesity-related conditions, particularly for people at high cardiovascular risk. Others urged caution, saying the guideline is an important international signal but that implementation, long-term monitoring, and attention to broader social drivers of obesity remain essential.
How GLP-1 drugs work and which are available
GLP-1 medications mimic a gut hormone that signals fullness to the brain, reducing appetite and calorie intake. Among the newer agents, two groups are commonly discussed:
– Tirzepatide-containing drugs (for example, Mounjaro and Zepbound), which act on multiple pathways and have produced some of the largest weight losses in trials.
– Semaglutide-containing drugs (for example, Ozempic and Wegovy), which also yield substantial weight loss and metabolic improvements.
Experts warn against treating all GLP-1s as interchangeable. Tirzepatide-class agents often deliver greater weight loss but tend to be more expensive, a distinction important for clinical decisions and policy.
Benefits beyond weight loss
Clinical studies suggest GLP-1 therapies can improve more than body weight when combined with lifestyle changes. Reported benefits include improved cardiometabolic markers, reductions in some obesity-related cancer risks in certain analyses, and lower hospitalization and mortality in particular heart-failure subgroups. Emerging research explores benefits for addiction and alcohol use, but magnitudes vary by drug, dose, population, and treatment duration.
Access, cost, and equity challenges
High prices, limited production capacity, and supply-chain constraints are major barriers to broad, equitable access. These obstacles are especially acute in low- and middle-income countries, where shortages of drugs, trained clinicians, counseling services, and comprehensive care systems limit practical use. WHO urged national policies to improve affordability, expand supply, and embed medications into integrated, sustainable obesity-care programs.
Practical considerations and long-term management
GLP-1s can meaningfully reduce appetite, cravings, and food preoccupation, and many patients report healthier food choices. However, therapy typically requires careful dose escalation, monitoring for gastrointestinal and other side effects, and often long-term use; significant weight regain commonly occurs after stopping treatment. Long-term safety data are still accumulating.
Most clinicians recommend beginning with diet, exercise, and behavioral supports and considering medication when lifestyle measures alone are insufficient or when obesity-related risks are high. Multidisciplinary, longitudinal care that combines nutrition and behavioral therapy, medication management, and surgical options when appropriate gives patients the best chance for durable results.
The broader drivers of obesity
In the United States, the CDC estimates roughly 40% of adults are obese. Obesity raises the risk of hypertension, type 2 diabetes, coronary heart disease, stroke, some cancers, sleep apnea, liver and gallbladder disease, pregnancy complications, and depression. While excess calorie intake and energy-dense diets are primary drivers, genetics, sleep deprivation, stress, aging, and the widespread availability of ultra-processed foods also contribute.
WHO recommendations going forward
WHO urges countries to incorporate GLP-1 therapies into broader strategies that combine medication with lifestyle interventions, counseling, and policy actions aimed at improving food environments and addressing social determinants of health. The agency called for more research on long-term outcomes and cost-effectiveness, and for measures to reduce prices so that treatments can reach people equitably.
Bottom line
The WHO guidance recognizes GLP-1 medications as effective tools when used within comprehensive obesity-treatment programs. Experts view these drugs as transformative for many patients, but stress that cost, access, long-term management, and integration with dietary, behavioral, and other medical supports are essential to realize their full public health benefit.